WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported that it had received notice from The NASDAQ Stock Market indicating that the closing bid price for its common stock for the last 30 consecutive business days was below the minimum $1.00 per share required for continued inclusion on The Nasdaq Capital Market. NeuroMetrix will have 180 calendar days, or until September 18, 2012, to regain compliance with the minimum bid rule. To regain compliance, its common stock must maintain a closing bid price of at least $1.00 per share for ten consecutive business days. The NASDAQ letter has no effect at this time on the listing of the Company’s common stock on The Nasdaq Capital Market.
